Advantages of T-Cell Immunotherapy Over CAR T-Cells

Video

AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.

“[Tab-cel] is actually really advantageous because when [patients] get the therapy, there's no special things people have to do. There's no premedication, you infuse therapy, watch the patients for 2 hours for vital stats, and if they walked in to get their therapy, they walk out and go back home. It's a very different administration profile than some of the other therapies.”

Atara Biotherapeutics is assessing tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the phase 3 ALLELE study (NCT03394365). They are reporting updated data at the upcoming American Society of Hematology 2021 Meeting, December 11-14.

Independent objective response rate was 50% (95% CI [33.4, 66.6]; n = 19) in the ALLELE study, which has enrolled 38 evaluable, heavily pretreated patients with EBV+ PTLD as of May 2021. Median duration of response could not yet be assessed, but 11 patients had a duration of response of at least 6 months. Investigators observed no new safety signals or concerns, and safety findings were consistent with previously published data.

GeneTherapyLive spoke with AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, to learn more about tab-cel and the advantages the therapy offers over other T-cell therapies, including chimeric antigen receptor (CAR) T-cell therapies.

REFERENCE
Atara Biotherapeutics to present eight abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, including first presentation of Tab-cel® pivotal phase 3 (ALLELE) data. News release. Atara Biotherapeutics. November 4, 2021. https://www.businesswire.com/news/home/20211104005811/en/Atara-Biotherapeutics-to-Present-Eight-Abstracts-at-the-63rd-American-Society-of-Hematology-ASH-Annual-Meeting-Including-First-Presentation-of-Tab-cel%C2%AE-Pivotal-Phase-3-ALLELE-Data
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.